Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 13/20 | 0.54 |
| ▸ | TTBK2 | Q6IQ55 | 13/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858840 | 0.84 | TTBK1 (0.59) | TTBK1TTBK2AURKAROCK1TNNI3K | |
| SCHEMBL858107 | 0.84 | TTBK1 (0.51) | TTBK1TTBK2AURKAAURKBROCK1 | |
| SCHEMBL858483 | 0.84 | ROCK1 (0.57) | TTBK1TTBK2AURKAAURKBROCK1 | |
| SCHEMBL857993 | 0.84 | TTBK1 (0.59) | TTBK1TTBK2AURKAAURKBROCK1 | |
| SCHEMBL858031 | 0.83 | TNNI3K (0.58) | TTBK1TTBK2AURKAAURKBROCK1 | |
| SCHEMBL857995 | 0.83 | ROCK2 (0.50) | TTBK1TTBK2AURKBROCK1TNNI3K | |
| SCHEMBL858341 | 0.80 | ROCK1 (0.50) | TTBK1TTBK2AURKBROCK1TNNI3K | |
| SCHEMBL857824 | 0.80 | ROCK1 (0.50) | TTBK1TTBK2AURKBROCK1TNNI3K | |
| SCHEMBL857983 | 0.80 | TTBK1 (0.62) | TTBK1TTBK2AURKAROCK1TNNI3K | |
| SCHEMBL858750 | 0.80 | ROCK1 (0.50) | TTBK1TTBK2AURKAAURKBROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008049855-A2 | 7-AZAINDOLE DERIVATIVES AS C-MET KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | TTBK1 2982/4885TTBK2 2930/4885AURKA 2839/4885 |
| US-20100016307-A1 | NOVEL COMPOUNDS | MET, HGF, HGFAC | TTBK1 1193/4885TTBK2 1622/4885AURKA 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.